GLP-1/GIP
Recent news mentioning GLP-1/GIP
- — Datos de fase III de olatorepatida --agonista dual sesgado de GLP-1/GIP de Hansoh-- presentados en la EASD
- — Spadek masy ciała o 19,3% po 48 tygodniach: na EASD zaprezentowano dane III fazy dotyczące olatorepatydu - agonisty receptorów GLP-1/GIP firmy Hansoh o ukierunkowanej sygnalizacji w obu receptorach
- — Perte de poids de 19,3 % à la 48e semaine : présentation lors de l'EASD des données de phase III concernant l'olatorepatide, l'agoniste à double action GLP-1/GIP développé par Hansohƒ
- — 19,3 % Gewichtsverlust in Woche 48: Daten der Phase-III-Studie zu Olatorepatid, Hansohs dualem, biased GLP-1/GIP-Agonisten, auf der EASD-Tagung vorgestellt
- — Kailera Therapeutics Announces Completion of Enrollment in KaiNETIC Global Phase 3 Clinical Program of GLP-1/GIP Receptor Dual Agonist Ribupatide Injection
- — Hengrui Pharma and Novo Enter Exclusive License Agreement for Once-Weekly Oral GLP-1/GIP Dual Receptor Agonist HRS-1596
- — Novo and Hengrui Pharma enter exclusive license agreement for once-weekly oral GLP-1/GIP dual receptor agonist HRS-1596
- — Viking Therapeutics Announces Positive Topline Results from Maintenance Study of GLP-1/GIP Agonist VK2735 Demonstrating the Promise of Multiple Maintenance Dosing Regimens
- — [Ad hoc announcement pursuant to Art. 53 LR] Roche announces positive Phase II results for dual GLP-1/GIP receptor agonist enicepatide in people living with type 2 diabetes and overweight or obesity